Stock comparison
United Therapeutics
Vir Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
VIR
Vir Biotechnology
Market cap
$1.55B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | UTHR | VIR | Winner |
|---|---|---|---|
| Warren Buffett | 71B | 20F | UTHR |
| Benjamin Graham | 76B | 37D | UTHR |
| Philip Fisher | 76B | 31F | UTHR |
| Peter Lynch | 62C | 3F | UTHR |
| Joel Greenblatt | 46D | 2F | UTHR |
| Charlie Munger | 64C | 38D | UTHR |
| Terry Smith | 64C | 38D | UTHR |
Side-by-side metrics
| Metric | UTHR | VIR |
|---|---|---|
| Market cap | $24.13B | $1.55B |
| P/E (TTM) | 19.2x | - |
| EV/EBIT | 15.2x | - |
| ROIC (TTM) | 18.81% | -48.49% |
| Gross margin | 86.58% | 2.75% |
| Net margin | 40.61% | -6.76% |
| Revenue CAGR 5y | 17.22% | -49.98% |
| EPS CAGR 5y | 29.84% | - |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
UTHR leads on
- ROIC (TTM)18.81%vs -48.49%+139%
- Revenue CAGR 5y17.22%vs -49.98%+134%
- Net margin40.61%vs -6.76%+106%
- Debt / Equity-vs 0.1x+100%
VIR leads on
- EV/EBIT-vs 15.2x+118%
- P/E (TTM)-vs 19.2x+115%
- Gross margin2.75%vs 86.58%+69%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.